BIOFRONTERA INC
BFRINASDAQ๐ #4769 by market capEarnings Mar 16 ยท PostUS Equity
$0.53โผ $0.04 (โ7.00%)
Market closed ยท at closeTrack BFRI
Get earnings, price moves & breaking news on Telegram
24hโผ 7.0%
7dโผ 24.5%
14dโผ 36.9%
30dโผ 33.2%
ytdโผ 11.6%
1yโผ 28.4%
๐ฆMarket Cap
$8M
Small Cap
๐Revenue Growth (YoY)
17.8%
Healthy
๐Gross Margin
79.3%
High
๐ตFCF Margin
โ
โ๏ธP/S Ratio
0.2x
Cheap
Otter Score
โ
Insufficient data
Trading Snapshot
- Day Range
- $0.53 โ $0.54
- 52-Week Range
- $0.54 โ $1.66
- Volume (shares)
- 2,626
- Avg Volume (shares)
- โ
- Shares Outstanding
- 14.8M
- Next Earnings
- 2027-03-16
Fundamentals Snapshot
- Annual Revenue
- $42M
- Last Q Revenue
- $9M
- P/E Ratio
- โ
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-0.59
- Dividend Yield
- โ
BIOFRONTERA INC
BFRIFinancial Trends
Financial history unavailable.
About BIOFRONTERA INC
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
๐ฆฆ
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
๐Qualityโ
โ
โ
โ
โ
๐Growthโ
โ
โ
โ
โ
โ๏ธValuationโ
โ
โ
โ
โ
Overall Score
Insufficient data
โ/100
Analyst Ratings
โConsensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.